BiBBInstruments AB announces outcome of subscription period for warrants of series TO 1

BiBBInstruments AB (”BiBB” or the ”Company”) today announces the outcome of the subscription period för warrants of series TO 1 (the ”Warrants” or ”TO 1”), which were issued in connection with the Company’s rights issue of units, the subscription period for which ended during the first quarter of 2025 (the “Rights Issue”). During the subscription period, which was held from May 22, 2025, to June 5, 2025, a total of 514,916 Warrants were exercised, corresponding to approximately 18.7 percent of all outstanding Warrants, for the subscription of 514,916 new shares in BiBB. The subscription price per share was SEK 3.25, which means that BiBB will receive approximately SEK 1,67 million before deduction of issue-related costs.

As a result of the exercise of the Warrants, the Company’s share capital will increase by 43,767.86 SEK, from SEK 3,419,072.81 to SEK 3,462,840.67, and the number of shares will increase by 514,916 shares, whereby the total number of shares in the Company will increase from 40,224,386 shares to 40,739,302 shares. This corresponds to a dilution effect of approximately 1.3 percent of the total number of shares and votes in the Company. Exercised Warrants have been replaced with interim shares (IA) pending registration of the new shares with the Swedish Companies Registration Office. Conversion of interim shares is expected to take place within approximately two (2) weeks.

Advisors
DNB Carnegie SME and Setterwalls Advokatbyrå AB acted as financial and legal advisors to BiBB in connection with the Rights Issue.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

About BiBB

BiBBInstruments AB (“BiBB”) develops and manufactures EndoDrill® – the world’s first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and EndoDrill® URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BIBB) is listed on Spotlight Stock Market.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.

Läs mer på Cision